Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Arcutis Biotherapeutics has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.
Arcutis Biotherapeutics's investors include RA Capital Management, BlackRock, Bain Capital, Vivo Capital, Goldman Sachs.
Arcutis Biotherapeutics is headquartered in Westlake Village, United States.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Arcutis Biotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arcutis Biotherapeutics — Funding & Investors." VCBacked, February 28, 2024, https://www.vcbacked.co/company/arcutis-biotherapeutics. Accessed September 29, 2026.
VCBacked. (2024). Arcutis Biotherapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/arcutis-biotherapeutics
{{cite web |title=Arcutis Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/arcutis-biotherapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated